Revenue: Up 16% to $803.7 million, and above guidance of about $790m.
Profit: Up 12% to $107.3m, and above guidance of between $95m and $105m.
Main takeaway: Questions have been raised about long-term growth expectations in a post-Covid world.
Analysts have probed the boss of Fisher & Paykel Healthcare about the longer-term growth expectations of hospital consumable sales after the listed device manufacturer reported interim results ahead of guidance.
The company today said its net profit after tax for the six months ended September 30
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
